Peptron (XKRX:087010) Debt-to-Equity : 0.28 (As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Peptron Debt-to-Equity?

Peptron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩4,590 Mil. Peptron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩4,520 Mil. Peptron's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₩32,096 Mil. Peptron's debt to equity for the quarter that ended in Mar. 2024 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Peptron's Debt-to-Equity or its related term are showing as below:

XKRX:087010' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.21 Max: 2.42
Current: 0.28

During the past 10 years, the highest Debt-to-Equity Ratio of Peptron was 2.42. The lowest was 0.04. And the median was 0.21.

XKRX:087010's Debt-to-Equity is ranked worse than
63.29% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs XKRX:087010: 0.28

Peptron Debt-to-Equity Historical Data

The historical data trend for Peptron's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Peptron Debt-to-Equity Chart

Peptron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

1.04

0.12

0.15

0.17

0.25

Peptron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.19	0.21	0.23	0.25	0.28

Competitive Comparison of Peptron's Debt-to-Equity

For the Biotechnology subindustry, Peptron's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Peptron's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Peptron's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Peptron's Debt-to-Equity falls into.

Peptron Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Peptron's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4606.89	+	4526.097)	/	36127.013
	=	0.25

Peptron's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4589.818	+	4519.571)	/	32096.368
	=	0.28

Peptron (XKRX:087010) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Peptron Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Peptron's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Peptron (XKRX:087010) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Peptron Inc (XKRX:087010) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

37-24, Yuseong-daero 1628 beon-gil, Yuseong-gu, Daejeon, KOR, 305811

Website

http://www.peptron.com

Peptron Inc is a biotechnology company engaged in developing fundamental technologies for peptide-based medicines. Its technology includes PeptrEX and SmartDepot. PeptrEX is an automatic system, enabling to synthesize simultaneously from a few to hundred types of peptides. SmartDepot is a proprietary ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of the drug. The group's research and development products include Luphere Depot for the treatment of prostate cancer and endometriosis, SR Exenatide PT302 AND SR EXENATIDE PT304 for the treatment of type II diabetes, SR Exenatide PT320 and 330 for the treatment of Parkinson's and Alzheimer's disease and SR Octreotide for the treatment of acromegaly and carcinoid tumor.

Peptron (XKRX:087010) Headlines

No Headlines